Search - tctmd.com

Displaying 801 - 820 of 872

Sort: Relevancy | Date

$Mobilized CD34+ Cells for Refractory Angina: Design and Update for the Phase 3 RENEW Study$

Presentation Cell Therapy 2013

Mobilized CD34+ Cells for Refractory Angina: Design and Update for the Phase 3 RENEW Study

Presenter: Thomas J. Povsic

January 22, 2013

News Daily News

Un Nuevo Anti Inflamatorio podría Reducir la Estenosis tras la Implantación de SMD en Pacientes de Alto Riesgo

L.A. McKeown

January 13, 2013

News Daily News

Novel Anti-inflammatory May Reduce Restenosis After BMS in High-Risk Patients

L.A. McKeown

January 13, 2013

News Daily News

La CABG es Más Rentable a Largo Plazo en Pacientes Diabéticos con Enfermedad Multivaso

Yael L. Maxwell

January 09, 2013

News Daily News

CABG More Cost-Effective in Patients with Diabetes, Multivessel Disease Over Long Term

Yael L. Maxwell

January 09, 2013

$Mobilized CD 34+ Cells for Refractory Angina$

Presentation TCT 2012

Mobilized CD 34+ Cells for Refractory Angina

Presenter: Thomas Povsic

October 22, 2012

News Conference News ESC 2012

ESC Congress 2012: Diverse Lineup of Practice-Changing Presentations

Caitlin E. Cox

September 04, 2012

News Conference News ESC 2012

Stem Cells, Nanoparticles Appear to be an Antidote to Atherosclerosis

Caitlin E. Cox

August 29, 2012

News Conference News ESC 2012

Comparable Long-Term Safety, Efficacy with Prasugrel, Clopidogrel in ACS

August 26, 2012

News Daily News

Perfusion Imaging Guidance for Revascularization Improves Outcomes

July 11, 2012

News Daily News

La Guía mediante Imágenes de Perfusión para la Revascularización Mejora los Resultados

July 11, 2012

News Daily News

Subanálisis del PLATO: El Ticagrelor es Rentable en Pacientes con SCA

June 26, 2012

News Daily News

PLATO Subanalysis: Ticagrelor Cost-Effective in ACS Patients

June 26, 2012

News Daily News

La Prueba de la Reactividad Coronaria es Relativamente Segura en Mujeres de Alto Riesgo Sin EAC

June 25, 2012

News Daily News

Coronary Reactivity Testing Relatively Safe in High-Risk Women Without CAD

June 25, 2012

News Daily News

Una Prueba Temprana de Esfuerzo Físico tras una PCI Primaria resulta Simple, Segura y Económica

May 10, 2012

News Daily News

Early Exercise Stress Testing After Primary PCI Simple, Safe, Economical

May 10, 2012

News Daily News

CHARISMA Genetics Analysis: CYP2C19 Variants Show Little Clinical Impact

April 10, 2012

News Daily News

Análisis Genético CHARISMA: Las Variantes del CYP2C19 Influyen Poco a Nivel Clínico

April 10, 2012

News Daily News

Un Registro de Nueva York Revela Mejores Resultados con la PCI que con el Tratamiento Médico en Pacientes Estables

Jason Kahn

April 03, 2012

Advertisement

Mobilized CD34+ Cells for Refractory Angina: Design and Update for the Phase 3 RENEW Study

Un Nuevo Anti Inflamatorio podría Reducir la Estenosis tras la Implantación de SMD en Pacientes de Alto Riesgo

Novel Anti-inflammatory May Reduce Restenosis After BMS in High-Risk Patients

La CABG es Más Rentable a Largo Plazo en Pacientes Diabéticos con Enfermedad Multivaso

CABG More Cost-Effective in Patients with Diabetes, Multivessel Disease Over Long Term

Mobilized CD 34+ Cells for Refractory Angina

ESC Congress 2012: Diverse Lineup of Practice-Changing Presentations

Stem Cells, Nanoparticles Appear to be an Antidote to Atherosclerosis

Comparable Long-Term Safety, Efficacy with Prasugrel, Clopidogrel in ACS

Perfusion Imaging Guidance for Revascularization Improves Outcomes

La Guía mediante Imágenes de Perfusión para la Revascularización Mejora los Resultados

Subanálisis del PLATO: El Ticagrelor es Rentable en Pacientes con SCA

PLATO Subanalysis: Ticagrelor Cost-Effective in ACS Patients

La Prueba de la Reactividad Coronaria es Relativamente Segura en Mujeres de Alto Riesgo Sin EAC

Coronary Reactivity Testing Relatively Safe in High-Risk Women Without CAD

Una Prueba Temprana de Esfuerzo Físico tras una PCI Primaria resulta Simple, Segura y Económica

Early Exercise Stress Testing After Primary PCI Simple, Safe, Economical

CHARISMA Genetics Analysis: CYP2C19 Variants Show Little Clinical Impact

Análisis Genético CHARISMA: Las Variantes del CYP2C19 Influyen Poco a Nivel Clínico

Un Registro de Nueva York Revela Mejores Resultados con la PCI que con el Tratamiento Médico en Pacientes Estables

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content